The calcium channel antagonist benidipine reduces plasma and cardiac endothelin-1 levels in type II diabetic rat model

Journal of Cardiovascular Pharmacology

Volumn 44, Issue SUPPL. 1, 2004, Pages

  Jesmin, Subrina ^a   Sakuma, Ichiro ^a   Hattori, Yuichi ^a   Kitabatake, Akira ^a   Miyauchi, Takashi ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Calcium channel blocker; Endothelin 1 (ET 1); Heart; Insulin resistance; Type 2 diabetes mellitus

Indexed keywords

BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD PRESSURE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; EXPERIMENTAL ANIMAL; INSULIN RESISTANCE; MALE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

AGE FACTORS; ANIMALS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENDOTHELIN-1; INSULIN RESISTANCE; MALE; MYOCARDIUM; RATS; RATS, INBRED OLETF; RATS, LONG-EVANS;

EID: 11144290197     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000166213.04674.c2     Document Type: Conference Paper

References (38)

1. Goto K, Hama H, Kasuya Y, et al. Molecular pharmacology and pathophysiological significance of endothelin. Jpn J Pharmacol. 1996;72:261-290.
2. Rich S, McLaughlin W. Endothelin receptor blockers in cardiovascular disease. Circulation. 2003;108:2184-2190.
3. Best PJ, Lerman A. Endothelin in cardiovascular disease: from atherosclerosis to heart failure. J Cardiovasc Pharmacol. 2000;35:S61-S63.
4. Greenberg BH. Endothelin and endothelin receptor antagonists in heart failure. Congest Heart Fail. 2002;8:257-261.
5. Myszka W, Kara-Perz H, Torlinski L. Endothelin-1 in coronary artery disease. Pol Merkuriusz Lek. 2001;11:291-294.
6. Braunstein S. New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione. Clin Ther. 2003;25:1895-1917.
7. Takeda Y, Miyamori I, Yoneda T, et al. Production of endothelin-1 from the mesenteric artery of streptozotocin-induced diabetic rats. Life Sci. 1991;48:2553-2556.
8. Makino A, Kamata K. Elevated plasma endothelin-1 level in streptozotocin-induced diabetic rats and responsiveness of mesenteric arterial bed to endothelin-1. Br J Pharmacol. 1998;123:1065-1072.
9. Hopfner RL, McNeill JR, Gopalakrishnan V. Endothelin plasma levels and endothelin-1 evoked vascular responses at different temporal stages of diabetes in streptozotocin rats. Eur J Pharmacol. 1999;374:221-227.
10. Donatelli M, Colletti I, Bucalo ML, et al. Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res Clin Pract. 1994;25:159-164.
11. Morise T, Takeuchi Y, Kawano M, et al. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care. 1997;18:87-89.
12. Cardillo C, Campia U, Bryant MB, et al. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002;106:1783-1787.
13. Anstadt MP, Hutchinson J, Portik-Dobos V, et al. Vascular endothelin converting enzyme-1 expression and activity is upregulated in clinical diabetes. Ethn Dis. 2002;12:S3-S9.
14. Deng D, Evans T, Mukherjee K, Downey D, et al. Diabetes induced vascular dysfunction in the retina: role of endothelins. Diabetologia. 1999;42:1228-1234.
15. Russell JC. Reduction and prevention of the cardiovascular sequelae of the insulin resistance syndrome. Curr Drug Targets Cardiovasc Haematol Disord. 2001;1:107-120.
16. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
17. Howard G, O'Leary DH, Zaccaro D, et al (for the IRAS Investigators). Insulin sensitivity and atherosclerosis. Circulation. 1996;93:1809-1817.
18. Ferri C, Bellini C, Desideri G, et al. Elevated plasma endothelin-1 levels as an additional risk factor in non-obese essential hypertensive patients with metabolic abnormalities. Diabetologia. 1997;40:100-102.
19. Piatti P, Monti LD, Conti M, et al. Hypertriglycemia and hyperinsulinemia are potent inducer of endothelin-1 release in humans. Diabetes. 1996;45:316-321.
20. Kawano K, Hirashima T, Mori S, et al. Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992;41:1422-1428.
21. Jesmin S, Sakuma I, Hattori Y, et al. Long-acting calcium channel blocker benidipine suppresses expression of angiogenic growth factors and prevents cardiac remodeling in a Type II diabetic rat model. Diabetologia. 2002;45:402-415.
22. Jesmin S, Hattori Y, Sakuma I, et al. Role of ANG II in coronary capillary angiogenesis at the insulin-resistant stage of a NIDDM rat model. Am J Physiol Heart Circ Physiol. 2002;283:H1387-H1397.
23. Fukuzawa Y, Watanabe Y, Inaguma D, et al. Evaluation of glomerular lesion and abnormal urinary findings in OLETF rats resulting from a long-term diabetic state. J Lab Clin Med. 1996;128:568-578.
24. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 2000;101:899-907.
25. Yagi K, Kim S, Wanibuchi H, et al. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima fatty rats. Hypertension. 1997;29:728-735.
26. Ferri C, Pittoni V, Piccoli A, et al. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab. 1995;80:829-835.
27. Olivert FJ, De la Rubia G, Feener EP, et al. Stimulation of endothelin-1 gene by insulin in endothelial cells. J Biol Chem. 1991;266:23251-23256.
28. Ferri C, Bellini C, Desideri G, et al. Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp Clin Endocrinol Diabetes. 1997;105:38-40.
29. Ferri C, Carlomagno A, Coassin S, et al. Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men. Diabetes Care. 1995;18:226-233.
30. Cernacek P, Stewart DJ, Monge JC, et al. The endothelin system and its role in acute myocardial infarction. Can J Physiol Pharmacol. 2003;81:598-606.
31. Giannessi D, Del Ry S, Vitale RL. The role of endothelins and their receptors in heart failure. Pharmacol Res. 2001;43:111-126.
32. B receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am J Physiol. 1999;276:H1197-H1206.
33. Grohe C, Nouskas J, Vetter H, et al. Effects of nisoldipine on endothelin-1- and angiotensin II-induced immediate/early gene expression and protein synthesis in adult rat ventricular cardiomyocytes. J Cardiovasc Pharmacol. 1994;24:13-16.
34. Haug C, Voisard R, Baur R, et al. Effect of diltiazem and verapamil on endothelin release by cultured human coronary smooth-muscle cells and endothelial cells. J Cardiovasc Pharmacol. 1118;31:S388-S391.
35. Kobayashi N, Nakano S, Mori Y, et al. Benidipine inhibits expression of ET-1 and TGF-β1 in Dahl salt-sensitive hypertensive rats. Hypertens Res. 2001;24:241-250.
36. Paul M, Zintz M, Bocker W, et al. Characterization and functional analysis of the rat endothelin-1 promoter. Hypertension. 1995;25:683-7.
37. Murphy TH, Worley PF, Baraban JM. L-type voltage-dependent calcium channels mediate synaptic activation of immediate early genes. Neuron. 1991;7:625-635.
38. Feron O, Salomone S, Godfraind T. Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats. Br J Pharmacol. 1996;118:659-664.